CompletedPhase 4NCT01965912
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
Studying Disorder of phenylalanin or tyrosine metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Ece Kucuksayrac, MDBioMarin Pharmaceutical
- Intervention
- Kuvan®(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 4-5 years · All sexes
- Timeline
- 2013 – 2023
Study locations (12)
- Research site, Munich, Germany
- Research site, Münster, Germany
- Research site, Bologna, Italy
- Research site - Bambino Gesu, Roma, Italy
- Research site - La Sapienza, Roma, Italy
- Research Site, Barcelona, Spain
- Research site, Murcia, Spain
- Research site, Santiago de Compostela, Spain
- Research site, Birmingham, United Kingdom
- Research site, Bristol, United Kingdom
- Research Site - Evelina, London, United Kingdom
- Research site - GOSH, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01965912 on ClinicalTrials.gov